Trust the science
Clinically validated in published, peer-reviewed research with Karolinska Institutet. Used by thousands of families over many years — significantly outperforming traditional treatment.
Key findings
Clinically validated in published, peer-reviewed research with Karolinska Institutet.
Roughly twice the effect of traditional treatment when using Evira.
Treatment effects maintained at three years (KI follow-up, 2025).
Compared with 11% in traditional care — particularly strong in adolescents.
Higher likelihood of reaching below the obesity threshold.
40% vs 85% cancelling over six months.
No ED diagnoses during or after treatment attributable to Evira.
Results exceed USPSTF benchmarks — which require ≥26 hours of professional support per year — with significantly lower resource requirements.
Significantly greater relative weight loss
In a one-year study with researchers from Karolinska Institutet, the first 107 patients at Martina Children's Hospital Centre for Weight Health used Evira for one year. A matched control group of 321 patients was randomly selected from the national quality register BORIS, receiving traditional treatment over the same period.
The intervention group using Evira achieved a relative weight reduction of 0.30 WHO BMI SDS units, compared with 0.15 in controls. A particularly strong effect was seen in adolescents — historically a group very difficult to reach with traditional treatment.
Hagman E, Johansson L, et al. International Journal of Obesity, 2022.
Long-term effects maintained — no weight regain
This follow-up from Karolinska Institutet — based on the same cohort of 428 children and adolescents (ages 4–17) — shows that the relative weight reduction achieved with Evira after one year was maintained for up to three years.
Weight loss maintained
Patients using Evira lost twice as much relative weight as the control group at one year — and held that reduction for three years.
Higher adherence
Significantly fewer patients dropped out compared with standard treatment.
70% more likely remission
Reaching a BMI below the obesity threshold, vs standard treatment.
No eating disorders
No patient using Evira developed an eating-disorder diagnosis during or in the year after treatment.
Hagman E, Lindberg L, et al. International Journal of Obesity, 2025.
Early validation across three clinics
Evira's initial phase was tested in a feasibility study at three clinics over six months. The study showed good treatment effect compared with traditional care. Almost all families using Evira reported it helped them reach their treatment goals and made it easier to contact clinicians, with significantly higher satisfaction than the control group.
Johansson L, Hagman E, Danielsson P. BMC Pediatrics, 2020.
Real-world implementation
Beyond clinical studies, Evira is deployed across 20+ CEW clinics in England (NHS England contract since 2023), 20+ paediatric clinics in Sweden, and adult weight management supporting 3,000+ adults.
Ongoing research
Several research projects are underway alongside the published studies.
EurEvira — international multicentre study
Evaluating Evira alongside local childhood-obesity treatment in several European countries.
Non-inferiority study, Abu Dhabi
60 patients at Sheikh Shakhbout Medical City followed for 26 weeks — comparing results with the Martina cohort. Study complete; article under review.
Evira + anti-obesity medication (RCT)
Randomised controlled trial at multiple Swedish clinics evaluating whether combining Evira with pharmacological treatment improves outcomes vs medication alone. Recruiting clinics.
Eating disorders & disordered eating
Multiple ongoing studies examining whether Evira affects prevalence of ED/DEB during and after treatment. Retrospective chart review of 315 patients.
Published research
Further publications are in progress — including the Abu Dhabi non-inferiority study (under review) and additional manuscripts in preparation.
Discuss the evidence
Our clinical and research team can walk you through the data. We also welcome research collaborations.